Rabab Debs1,2, Pauline Reach1,2, Corina Cret3, Sophie Demeret2, Samir Saheb4, Thierry Maisonobe1,2, Karine Viala1,2. 1. a Département de Neurophysiologie , Groupe Hospitalier Pitié-Salpêtriére , AP-HP , Paris , France. 2. c Service de neurologie 1, Centre diagnostique et thérapeutique des neuropathies périphériques , Groupe Hospitalier Pitié-Salpêtriére , AP-HP , Paris , France. 3. b Neurology Department , Centre Hospitalier de Meaux , Meaux , France. 4. d Centre Clinique d'Hémobiothérapie, service d'Hématologie , Groupe Hospitalier Pitié-Salpêtrière , AP-HP , Paris , France.
Abstract
BACKGROUND: Chronic inflammatory demyelinating polyneuropathy (CIDP) is treated with intravenous immunoglobulins (IVIg), corticosteroids or plasma exchange (PE). IVIg dosage is not universal and markers for treatment management are needed. METHODS: We report the response to high-dose and fractioned IVIg in a subgroup of definite CIDP patients, resistant to corticosteroids and PE, responders to IVIg but with an efficacy window <15 d. RESULTS: Four patients were included with similar predominantly clinical motor form and conduction abnormalities. Treatment management consisted of fractioning IVIg and increasing the monthly cumulated dose (mean: 3 g/kg/month). Serum IgG concentration was measured and correlated to the clinical state. Monitoring of serum IgG helped to guide IVIg administration dosage and frequency. A mean of 10 months was required to improve symptoms; therapy was then switched to subcutaneous (SC) route (maintenance dose: 3.5 g/kg/month). The mean Overall Neuropathy Limitations Scale was improved from 11 to 3.2 and the mean Medical Research Council scale from 26 to 90. CONCLUSION: It is important to distinguish patients with short IVIg efficacy window from those with classical resistance since the former may benefit from fractioning and increasing the IVIg dose. The monitoring of serum IgG level and its correlation to the clinical response could be of help in monitoring each individual's dosage.
BACKGROUND: Chronic inflammatory demyelinating polyneuropathy (CIDP) is treated with intravenous immunoglobulins (IVIg), corticosteroids or plasma exchange (PE). IVIg dosage is not universal and markers for treatment management are needed. METHODS: We report the response to high-dose and fractioned IVIg in a subgroup of definite CIDPpatients, resistant to corticosteroids and PE, responders to IVIg but with an efficacy window <15 d. RESULTS: Four patients were included with similar predominantly clinical motor form and conduction abnormalities. Treatment management consisted of fractioning IVIg and increasing the monthly cumulated dose (mean: 3 g/kg/month). Serum IgG concentration was measured and correlated to the clinical state. Monitoring of serum IgG helped to guide IVIg administration dosage and frequency. A mean of 10 months was required to improve symptoms; therapy was then switched to subcutaneous (SC) route (maintenance dose: 3.5 g/kg/month). The mean Overall Neuropathy Limitations Scale was improved from 11 to 3.2 and the mean Medical Research Council scale from 26 to 90. CONCLUSION: It is important to distinguish patients with short IVIg efficacy window from those with classical resistance since the former may benefit from fractioning and increasing the IVIg dose. The monitoring of serum IgG level and its correlation to the clinical response could be of help in monitoring each individual's dosage.
Authors: Jeffrey A Allen; Melvin Berger; Luis Querol; Krista Kuitwaard; Robert D Hadden Journal: J Peripher Nerv Syst Date: 2018-04-19 Impact factor: 3.494
Authors: K Kuitwaard; E Brusse; B C Jacobs; A F J E Vrancken; F Eftimov; N C Notermans; A J van der Kooi; W-J R Fokkink; D Nieboer; H F Lingsma; I S J Merkies; P A van Doorn Journal: Eur J Neurol Date: 2020-10-01 Impact factor: 6.089
Authors: Michael A Tortorici; Theresa Yuraszeck; David Cornblath; Vera Bril; Hans-Peter Hartung; Gen Sobue; Richard A Lewis; Ingemar S J Merkies; John-Philip Lawo; Michaela Praus; Billie L Durn; Orell Mielke; Xuewen Ma; Petra Jauslin; Marc Pfister; Ivo N van Schaik Journal: CPT Pharmacometrics Syst Pharmacol Date: 2021-08-01